These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35783125)

  • 1. The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort.
    Qin Q; Wan H; Wang D; Li J; Qu Y; Zhao J; Li J; Xue Z
    Front Aging Neurosci; 2022; 14():892493. PubMed ID: 35783125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of soluble TREM2 on motor progression in Parkinson's disease.
    Zhang X; Zhong X; Wang L; Li H; Yang L; Li X; Yu X; Xie A
    Neurosci Lett; 2023 Jun; 807():137277. PubMed ID: 37105353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Triggering Receptor Expressed on Myeloid Cells 2 From Cerebrospinal Fluid in Sleep Disorders Related to Parkinson's Disease.
    Mo M; Tang Y; Wei L; Qiu J; Peng G; Lin Y; Zhou M; Dai W; Zhang Z; Chen X; Liu H; Ding L; Ye P; Wu Y; Zhu X; Wu Z; Guo W; Xu P
    Front Aging Neurosci; 2021; 13():753210. PubMed ID: 34658845
    [No Abstract]   [Full Text] [Related]  

  • 4. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
    Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study.
    Nabizadeh F; Seyedmirzaei H; Karami S
    Sci Rep; 2024 Jul; 14(1):15318. PubMed ID: 38961148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease.
    Tao M; Dou K; Xie Y; Hou B; Xie A
    Front Neurosci; 2022; 16():1049118. PubMed ID: 36507360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
    Li TR; Lyu DY; Liu FQ;
    J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes.
    Pillai JA; Khrestian M; Bena J; Leverenz JB; Bekris LM
    Front Aging Neurosci; 2021; 13():676744. PubMed ID: 34276339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Cerebrospinal Fluid Soluble TREM2 and Polymorphisms in Sporadic Parkinson's Disease in a Chinese Population.
    Peng G; Qiu J; Liu H; Zhou M; Huang S; Guo W; Lin Y; Chen X; Li Z; Li G; Zhang W; Zhang Y; Li X; Wu Z; Wei L; Yang X; Zhu X; Mo M; Xu P
    J Mol Neurosci; 2020 Feb; 70(2):294-301. PubMed ID: 31833018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
    Nabizadeh F; Pirahesh K; Valizadeh P
    J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson's disease.
    Nabizadeh F; Sodeifian F; Kargar A
    Acta Neurol Belg; 2023 Aug; 123(4):1429-1437. PubMed ID: 37000407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.